287 Spam-Free Article(s) Found
Sort:
Date
Filter:
All
Symbol Name Last Close Mkt Cap DailyStocks'
Rating
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Monday’s Close
INCY Incyte Corporation $67.04 $14.25B N/A
Article Searches
Lessons to Learn From April's Biotech Blowups https://www.fool.com/investing/2018/04/25/lessons-to-learn-from-aprils-biotech-blowups.aspx?source=iedfolrf0000001 Apr 25, 2018 - Three biotechs reported devastating clinical trial failures this month. Here are the important takeaways.
Is Eli Lilly and Company a Buy? https://www.fool.com/investing/2018/04/25/is-eli-lilly-and-company-a-buy.aspx?source=iedfolrf0000001 Apr 25, 2018 - Lilly's first-quarter results looked good. Is it time to buy the big pharma stock?
Lilly (LLY) Tops on Q1 Earnings, Raises '18 View, Stock Up http://www.zacks.com/stock/news/300433/lilly-lly-tops-on-q1-earnings-raises-18-view-stock-up?cid=CS-ZC-FT-300433 Apr 24, 2018 - Eli Lilly (LLY) beats estimates for both earnings and sales in Q1 and raises guidance for 2018. Shares rise in pre-market trading.
3 Biotech Stocks With Major Catalysts Incoming https://www.fool.com/investing/2018/04/20/3-biotech-stocks-with-huge-catalysts-incoming.aspx?source=iedfolrf0000001 Apr 20, 2018 - Highly anticipated events expected in the weeks ahead could set these three biotechs up for long-term success.
Lilly (LLY) to Report Q1 Earnings: What's in the Cards? http://www.zacks.com/stock/news/300046/lilly-lly-to-report-q1-earnings-whats-in-the-cards?cid=CS-ZC-FT-300046 Apr 20, 2018 - Lilly's (LLY) new drugs like Trulicity, Taltz and Jardiance have been performing well. Let's see if these along with its older products lead the company to an earnings beat.
What Incyte's Phase 3 Fail Means for Immuno-Oncology https://www.fool.com/investing/2018/04/16/what-incytes-phase-3-fail-means-for-immuno-oncolog.aspx?source=iedfolrf0000001 Apr 16, 2018 - Incyte’s phase 3 Epacadostat trial wasn’t so hot, and stocks all across biotech are feeling the burn.
What's Next for Incyte? https://www.fool.com/investing/2018/04/16/whats-next-for-incyte.aspx?source=iedfolrf0000001 Apr 16, 2018 - With a key pipeline drug nixed, Incyte has a few more question marks on the horizon than it did before.
The Zacks Analyst Blog Highlights: Agios Pharmaceuticals, BioMarin Pharmaceutical, Vertex Pharmaceuticals and Incyte http://www.zacks.com/stock/news/299249/the-zacks-analyst-blog-highlights-agios-pharmaceuticals-biomarin-pharmaceutical-vertex-pharmaceuticals-and-incyte?cid=CS-ZC-FT-299249 Apr 16, 2018 - The Zacks Analyst Blog Highlights: Agios Pharmaceuticals, BioMarin Pharmaceutical, Vertex Pharmaceuticals and Incyte
What Happened With Incyte's IDO Inhibitor Flop https://www.fool.com/investing/2018/04/13/what-happened-with-incytes-ido-inhibitor-flop.aspx?source=iedfolrf0000001 Apr 13, 2018 - Investor confidence in epacadostat was through the roof, and the drug's phase 3 flop crushed the stock in a big way.
Pharma M&A Active This Week: 4 Potential Buyout Targets http://www.zacks.com/stock/news/299114/pharma-ma-active-this-week-4-potential-buyout-targets?cid=CS-ZC-FT-299114 Apr 13, 2018 - Novartis and Alexion announce respective acquisitions of AveXis and Wilson Therapeutics for a pipeline boost. We suggest four stocks as hot acquisition picks this year.

Pages: 1...89101112131415161718...29

<<<Page 13>